Cargando…

Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis

A high allele burden of the KIT D816V mutation in peripheral blood or bone marrow aspirates indicates multi-lineage hematopoietic involvement and has been associated with an aggressive clinical course of systemic mastocytosis. Since mast cells are substantially underrepresented in these liquid speci...

Descripción completa

Detalles Bibliográficos
Autores principales:	Greiner, Georg, Gurbisz, Michael, Ratzinger, Franz, Witzeneder, Nadine, Class, Svenja Verena, Eisenwort, Gregor, Simonitsch-Klupp, Ingrid, Esterbauer, Harald, Mayerhofer, Matthias, Müllauer, Leonhard, Sperr, Wolfgang R., Valent, Peter, Hoermann, Gregor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012478/ https://www.ncbi.nlm.nih.gov/pubmed/31018976 http://dx.doi.org/10.3324/haematol.2019.217950

Ejemplares similares

Engraftment in NSG(SCF) mice correlates with the WHO category and prognosis in systemic mastocytosis
por: Willmann, Michael, et al.
Publicado: (2023)

Genetic Regulation of Tryptase Production and Clinical Impact: Hereditary Alpha Tryptasemia, Mastocytosis and Beyond
por: Sprinzl, Bettina, et al.
Publicado: (2021)

FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H()
por: Valent, Peter, et al.
Publicado: (2013)

A Multidisciplinary Intervention in Childhood Obesity Acutely Improves Insulin Resistance and Inflammatory Markers Independent From Body Composition
por: Mayerhofer, Ernst, et al.
Publicado: (2020)

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis
por: Schneeweiss, Mathias, et al.
Publicado: (2018)

Systemic mastocytosis associated with chronic myelomonocytic leukemia and xanthogranuloma
por: Tschandl, Philipp, et al.
Publicado: (2012)

CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1(T315I)+ clones in TKI-resistant CML
por: Schneeweiss-Gleixner, Mathias, et al.
Publicado: (2019)

CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V(+) Neoplastic Mast Cells
por: Schneeweiss-Gleixner, Mathias, et al.
Publicado: (2022)

Identification of bromodomain-containing protein 4 (BRD4) as a novel marker and epigenetic target in mast cell leukemia
por: Wedeh, Ghaith, et al.
Publicado: (2015)

Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis
por: Nedoszytko, Boguslaw, et al.
Publicado: (2021)

Incidence of symptomatic Covid‐19 infections in patients with mastocytosis and chronic myeloid leukemia: A comparison with the general Austrian population
por: Graf, Irene, et al.
Publicado: (2022)

Preclinical human models and emerging therapeutics for advanced systemic mastocytosis
por: Arock, Michel, et al.
Publicado: (2018)

Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms
por: Hoermann, Gregor, et al.
Publicado: (2015)

TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML
por: Valent, Peter, et al.
Publicado: (2017)

Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches
por: Valent, Peter, et al.
Publicado: (2019)

Chloroquine inhibits human CD4(+) T-cell activation by AP-1 signaling modulation
por: Schmidt, Ralf L. J., et al.
Publicado: (2017)

Clonal Hematopoiesis of Indeterminate Potential: A Multidisciplinary Challenge in Personalized Hematology
por: Hoermann, Gregor, et al.
Publicado: (2020)

Cell‐based and antibody‐mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: Perspectives and open issues
por: Valent, Peter, et al.
Publicado: (2020)

Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia
por: Cerny-Reiterer, Sabine, et al.
Publicado: (2014)

The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells
por: Stefanzl, Gabriele, et al.
Publicado: (2017)

Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML
por: Valent, Peter, et al.
Publicado: (2019)

STAT5 is Expressed in CD34(+)/CD38(−) Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms
por: Hadzijusufovic, Emir, et al.
Publicado: (2020)

Massive release of the histamine‐degrading enzyme diamine oxidase during severe anaphylaxis in mastocytosis patients
por: Boehm, Thomas, et al.
Publicado: (2019)

BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph(+) chronic myeloid leukemia
por: Peter, Barbara, et al.
Publicado: (2022)

Identification of a Leukemia-Initiating Stem Cell in Human Mast Cell Leukemia
por: Eisenwort, Gregor, et al.
Publicado: (2019)

Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm
por: Füreder, Wolfgang, et al.
Publicado: (2016)

Phenotyping and Target Expression Profiling of CD34(+)/CD38(−) and CD34(+)/CD38(+) Stem- and Progenitor cells in Acute Lymphoblastic Leukemia
por: Blatt, Katharina, et al.
Publicado: (2018)

Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts
por: Valent, Peter, et al.
Publicado: (2023)

Mastocytosis, MCAS, and Related Disorders—Diagnosis, Classification, and Therapy
por: Niedoszytko, Marek, et al.
Publicado: (2021)

Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia
por: Gleixner, Karoline V., et al.
Publicado: (2017)

Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells
por: Peter, Barbara, et al.
Publicado: (2017)

Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives
por: Valent, Peter, et al.
Publicado: (2018)

Mediator-Related Symptoms and Anaphylaxis in Children with Mastocytosis
por: Brockow, Knut, et al.
Publicado: (2021)

Biological properties of bone marrow plasma cells influence their recovery in aspirate specimens: impact on classification of plasma cell disorders and potential bias to evaluation of treatment response
por: Demyanets, Svitlana, et al.
Publicado: (2020)

LMO3 reprograms visceral adipocyte metabolism during obesity
por: Wagner, Gabriel, et al.
Publicado: (2021)

Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site
por: Hadzijusufovic, Emir, et al.
Publicado: (2017)

Identification of CD203c as a New Basophil-Specific Flow-Marker in Ph(+) Chronic Myeloid Leukemia
por: Sadovnik, Irina, et al.
Publicado: (2022)

Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study
por: Snijder, Berend, et al.
Publicado: (2017)

COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)
por: Bonadonna, Patrizia, et al.
Publicado: (2021)

Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era
por: Porpaczy, Edit, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b24b64u6u5a42n6mfoq8rf9ora